Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14307MR)

This product GTTS-WQ14307MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Solid tumors, Colorectal Cancer (CRC) Cancers (CRC) Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ14307MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2068MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ7397MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ15004MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ1947MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AGS15C
GTTS-WQ1891MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AGEN2034
GTTS-WQ12177MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-009
GTTS-WQ4298MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ7551MR IVTScrip™ mRNA-Anti-GPC3, GC33(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GC33
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW